An investigation on behalf of current long term investors in Ocular Therapeutix Inc (NASDAQ:OCUL) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:OCUL stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 11/30/2017 -- An investigation on behalf of current long-term investors in shares of Ocular Therapeutix Inc (NASDAQ:OCUL) concerning potential breaches of fiduciary duties by certain directors and officers of Ocular Therapeutix was announced.
Investors who are current long term investors in Ocular Therapeutix Inc (NASDAQ:OCUL) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm for investors in NASDAQ:OCUL stocks follows a lawsuit pending against Ocular Therapeutix Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:OCUL stocks, concerns whether certain Ocular Therapeutix directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges on behalf of certain purchasers of Ocular Therapeutix Inc (NASDAQ:OCUL) common shares that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 5, 2017 and July 6, 2017 Ocular Therapeutix issued false and/or misleading statements and/or failed to disclose that Ocular Therapeutix's management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product that such manufacturing issues could imperil the approval of DEXTENZA by the FDA, and that as a result, defendants' public statements were materially false and misleading at all relevant times.
Those who purchased shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels